BioCentury | Apr 21, 2020
Product Development

Cara’s pruritus therapy headed for submission after second Phase III readout

...results follow last year’s readout from the U.S. Phase III KALM-1 trial, in which the KOR...
...$15.42. Targets KOR (OPRK1) - κ opioid receptor Paul Bonanos, Associate Editor Korsuva, difelikefalin (IV CR845) Cara Therapeutics Inc. Kappa opioid receptor (KOR) (OPRK1)...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...long-acting peripheral KOR agonist. Targets: CCR4 (CD194) - CC chemokine receptor 4; KOR (OPRK1) - Kappa opioid receptor...
BioCentury | Aug 22, 2019
Tools & Techniques

Digital makes its mark on cognition

...our development of digital biomarkers going forward,” she added. BlackThorn’s lead candidate, a Phase I KOR...
...OTCQX:RHHBY), Basel, Switzerland Winterlight Labs Inc., Toronto, Ont. Targets HTT - Huntingtin KOR (OPRK1) - Kappa opioid receptor Allison...
BioCentury | Jul 25, 2019
Financial News

July 25 Financial Quick Takes: Livongo, Castle pop after IPOs; plus a K2HV-Evelo deal, earnings beats for AZ & Roche, and more

...this half from a second Phase III trial of long-acting peripheral κ opioid receptor (KOR; OPRK1...
BioCentury | Jun 13, 2019
Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

...PathFinder, which will inform patient segmentation in future trials. BlackThorn’s lead asset is BTRX-335140, a KOR...
...with the financing, Sunderland, Hu and Polaris’ Brian Chee joined BlackThorn’s board. Targets: KOR - Kappa opioid receptor...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

...symptoms Buprenorphine Approved to treat OUD in 2002 Partial MOR agonist, κ opioid receptor (KOR; OPRK1...
...poor compliance until extended release ER formulation was approved for OUD in 2010 MOR antagonist, KOR...
BioCentury | May 30, 2019
Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

...Data from the Phase III KALM-2 trial of the long-acting peripheral κ opioid receptor (KOR; OPRK1...
BioCentury | Apr 8, 2019
Financial News

Itch company Trevi files for IPO

...chronic liver disease. The therapy is an oral, extended-release formulation of a MOR antagonist and KOR...
...while New Enterprise Associates holds 20.6%, Lundbeckfonden Ventures 8.3% and Omega Funds 6.2%. Targets: KOR (OPRK1...
BioCentury | Jan 11, 2019
Clinical News

BlackThorn deprioritizing MDD compound after Phase IIa miss

...Co. (NYSE:LLY). The company's next most advanced product is BTRX-335140, a κ opioid receptor (KOR; OPRK1...
BioCentury | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

...muscarinic receptor inhibitors, estrogen receptor agonists, EZH2 inhibitors, imidazole antifungals and additional compound classes (see “KOR-recting...
...their canonical targets. The compounds included clemastine and benztropine, which inhibit CHRM1, and U50488, a KOR...
...P450 C-14 α demethylase EBP - EBP cholesterol Δ-isomerase IGF1 - Insulin-like growth factor-1 KOR (OPRK1...
Items per page:
1 - 10 of 185